ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Conditions:   Castration-Resistant Prostate Carcinoma;   Metastatic Prostate Adenocarcinoma;   Metastatic Prostate Small Cell Carcinoma;   Stage IV Prostate Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8 Interventions:   Drug: BET Bromodomain Inhibitor ZEN-3694;   Drug: Enzalutamide;   Biological: Pembrolizumab Sponsors:   Rahul Aggarwal;   Zenith Epigenetics;   Merck Sharp & Dohme Corp.;   U.S. Army Medical Research and Development Command Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials